Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

p>

  • Top line results from the phase II trial in healthy adults with our trivalent seasonal flu vaccine candidate;
  • Preclinical results of studies with vaccine candidates against the Respiratory Syncitial Virus (RSV);
  • Commencement of operations of the joint venture with Cadila Pharmaceuticals Ltd in India; and,
  • Initiation of a Phase II clinical study of our trivalent seasonal flu vaccine in older adults.

2009 Financial Results

Revenue from operations for the first quarter ended March 31, 2009 was $0.02 million compared to $0.5 million for the same period in 2008, a net decrease of $0.4 million due to the completion of a government contract in the first quarter of 2009.

Research and development costs for the first quarter of 2009 were $4.3 million compared to $4.4 million in the first quarter of 2008. The decrease was due to a $0.2 million decrease in employee costs and a $0.1 million decrease associated with the closing of the Taft Court facility in October 2008 when the Company consolidated its operations into the Belward Campus facility. These decreases were partially offset by an increase in $0.1 million in outside testing costs associated with the continuing clinical trials, preclinical testing, process development, manufacturing and quality related programs and a $0.1 million increase in facility costs.

General and administrative costs were $2.9 million in the first quarter of 2009 as compared to $3.2 million in the first quarter of 2008. The $0.3 million decrease was due to a decrease in employee costs of $0.1 million, a decrease in facility costs associated with general and administrative functions of $0.1 million, and a decrease of $0.2 million in charges to the allowance established for two notes receivable from former directors. The Company determined that the notes receivable
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... element of surprise has been a major advantage of ... Until now, epidemiologists had nothing to measure that might ... suboptimal responses to both the H1N1 pandemic of 2009 ... http://photos.prnewswire.com/prnh/20141121/160242 That virus advantage ... structural changes have been found that invariably to date ...
(Date:11/21/2014)... , November 21, 2014 , ... comercial   Mariano Rodríguez es elegid vicepresidente ... KLOX está en marcha para comenzar de forma ... de heridas de reciente aprobación en Europa   , ... se complace al anunciar los siguientes nombramientos: ...
(Date:11/21/2014)... (PRWEB) November 19, 2014 The science ... lives was shared with more than 200 primary students ... students from the University of Otago Physics Department and ... The Otago students, members of the university’s OSA/SPIE Student ... in early September, giving children from small, rural schools ...
(Date:11/21/2014)... Los Angeles, CA (PRWEB) November 20, 2014 ... “A Short Walk to the Other Side” ... was an “Award-Winning Finalist in the “Fiction: Short Story” ... . , Jeffrey Keen, President and CEO of USA ... entries from mainstream and independent publishers, including Simon & ...
Breaking Biology Technology:Viruses' Advantage of Surprise is Lost 2KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5Optics and photonics outreach programs share science, spark fascination with light 2Optics and photonics outreach programs share science, spark fascination with light 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4
... VEENENDAAL, The Netherlands, June 2 ... today announced the creation,of an exclusive partnership and ... for an undisclosed sum. The two companies, headquartered ... the combination,will strengthen Nucletron,s position as global leader ...
... The American Institute of Aeronautics and Astronautics ... top emerging aerospace technologies. Developed by AIAA,s ... following: 1. "Greener Aviation" Technologies including emission ... the Federal Aviation Administration,s Continuous Low Emissions, Energy ...
... First Randomized Trial to Demonstrate Superior Clinical Benefit in Relapsed/Refractory Aggressive NHL , ... to treat Analysis results per FDA agreed upon Statistical Analysis Plan , ... Significant Increase in Complete Remission Rates 20% vs. 5.7%; p=0.021 ... Rate 37.1% vs. 14.3%; p=0.003 , ...
Cached Biology Technology:Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market 2Dutch Medical Equipment Producer Nucletron Strengthens Leading Position in Cancer Radiation Therapy Market 3AIAA names top ten emerging aerospace technologies of 2009 2Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 2Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 3Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 4Pixantrone Significantly Increases Complete Remissions, Overall Response Rates, Frequency of Durable Remissions and Progression Free Survival in Patients with Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma 5
(Date:11/6/2014)... paper from a team of Florida State University biologists ... could adapt to and survive environmental swings such as ... latest issue of the journal The Plant Cell ... DNA and proteins) is organized in a cell and ... are turned on and others are turned off. , ...
(Date:11/6/2014)... - Insilico Medicine, Inc, a Baltimore-based bioinformatics company ... diseases announced a research collaboration with the international ... Inc (OTC: CSBR). , "There are many companies ... Champions Oncology,s TumorGraft technology is unique in a ... experimentally generating vast amounts of valuable data. Our ...
(Date:11/5/2014)... great diversity in their ability to identify scents and ... in their perceptual evaluation of odors, with women outperforming ... , Sex differences in olfactory detection may play a ... to one,s perception of smell, which is naturally linked ... has been suggested to be cognitive or emotional, rather ...
Breaking Biology News(10 mins):Maize analysis yields whole new world of genetic science 2Insilico Medicine, Inc announces research collaboration with Champions Oncology, Inc 2The female nose always knows: Do women have more olfactory neurons? 2
... University of Copenhagen lead the way for future monitoring of ... samples to keep track of fish and whales in the ... local fish and whale faunas and combat traditional fishing methods. ... PLOS ONE . "The new DNA-method means that ...
... political targets to significantly reduce and halt biodiversity loss. ... setting up of new targets for 2020. In addition, ... been incorporated in several global and the EU agendas ... a critical review of the existing and emerging biodiversity ...
... the political targets to significantly reduce and halt biodiversity ... the setting up of new targets for 2020. In ... has been incorporated in several global and the EU ... requires a critical review of the existing and emerging ...
Cached Biology News:New DNA-method tracks fish and whales in seawater 2Biodiversity conservation depends on scale: Lessons from the science-policy dialogue 2Biodiversity conservation depends on scale: Lessons from the sience-policy dialogue 2
The Zymo-Spin PI Fast-Spin column features durable polypropylene construction and is the same column featured in the His-Spin Protein Miniprep. Capacity is 800 l....
X-gal,1g...
Standard 2" or 3" Plastic can be ordered with 81 or 100 cell dividers. Mini 2" Plastics Boxes come standard with 25 cell dividers. Plastic boxes can also be ordered with corresponding freezer racks...
... Quantities to Kilograms, Multiple ... Special amino acids and their derivatives, ... AMC, aldehyde, CMK, Purity from ... Chromogenic/Flurogenic Substrates, Solid Phase/Solution/Segment Coupling ...
Biology Products: